Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.75
NAS:ARRY's Cash-to-Debt is ranked lower than
76% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:ARRY: 1.75 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ARRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.63 Max: No Debt
Current: 1.75
Equity-to-Asset 0.04
NAS:ARRY's Equity-to-Asset is ranked lower than
92% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:ARRY: 0.04 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ARRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.46  Med: 0.23 Max: 0.93
Current: 0.04
-1.46
0.93
Debt-to-Equity 11.42
NAS:ARRY's Debt-to-Equity is ranked lower than
98% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:ARRY: 11.42 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ARRY' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.52  Med: -0.3 Max: 11.42
Current: 11.42
-4.52
11.42
Piotroski F-Score: 4
Altman Z-Score: -0.27
Beneish M-Score: -4.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -67.67
NAS:ARRY's Operating Margin % is ranked higher than
55% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:ARRY: -67.67 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ARRY' s Operating Margin % Range Over the Past 10 Years
Min: -410.11  Med: -63.65 Max: 6.34
Current: -67.67
-410.11
6.34
Net Margin % -77.44
NAS:ARRY's Net Margin % is ranked higher than
52% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:ARRY: -77.44 )
Ranked among companies with meaningful Net Margin % only.
NAS:ARRY' s Net Margin % Range Over the Past 10 Years
Min: -511.63  Med: -83.68 Max: 18.05
Current: -77.44
-511.63
18.05
ROE % -40646.49
NAS:ARRY's ROE % is ranked lower than
99.99% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:ARRY: -40646.49 )
Ranked among companies with meaningful ROE % only.
NAS:ARRY' s ROE % Range Over the Past 10 Years
Min: -40646.49  Med: -132.15 Max: 110.67
Current: -40646.49
-40646.49
110.67
ROA % -51.09
NAS:ARRY's ROA % is ranked lower than
67% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:ARRY: -51.09 )
Ranked among companies with meaningful ROA % only.
NAS:ARRY' s ROA % Range Over the Past 10 Years
Min: -99.03  Med: -51.46 Max: 5.6
Current: -51.09
-99.03
5.6
ROC (Joel Greenblatt) % -1375.06
NAS:ARRY's ROC (Joel Greenblatt) % is ranked lower than
62% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:ARRY: -1375.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ARRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1410.82  Med: -321.97 Max: 297.05
Current: -1375.06
-1410.82
297.05
3-Year Revenue Growth Rate 39.40
NAS:ARRY's 3-Year Revenue Growth Rate is ranked higher than
67% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:ARRY: 39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ARRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -2.2 Max: 39.8
Current: 39.4
-35.9
39.8
3-Year EBITDA Growth Rate 2.90
NAS:ARRY's 3-Year EBITDA Growth Rate is ranked higher than
59% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. NAS:ARRY: 2.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ARRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: 2.7 Max: 105.1
Current: 2.9
-66.3
105.1
3-Year EPS without NRI Growth Rate 1.40
NAS:ARRY's 3-Year EPS without NRI Growth Rate is ranked higher than
57% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. NAS:ARRY: 1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ARRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: 1.4 Max: 55.7
Current: 1.4
-50.5
55.7
GuruFocus has detected 4 Warning Signs with Array BioPharma Inc $NAS:ARRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ARRY's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ARRY Guru Trades in Q3 2016

Paul Tudor Jones 135,000 sh (New)
Joel Greenblatt 16,705 sh (New)
Jim Simons 424,452 sh (+2332.11%)
Ken Fisher 135,895 sh (+0.15%)
» More
Q4 2016

ARRY Guru Trades in Q4 2016

Steven Cohen 1,570,641 sh (New)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Ken Fisher 65,693 sh (-51.66%)
» More
Q1 2017

ARRY Guru Trades in Q1 2017

Caxton Associates 15,900 sh (New)
Ken Fisher 78,014 sh (+18.76%)
Steven Cohen 500,000 sh (unchged)
Steven Cohen 1,277,900 sh (-18.64%)
» More
Q2 2017

ARRY Guru Trades in Q2 2017

Paul Tudor Jones 73,373 sh (New)
Jim Simons 990,441 sh (New)
Steven Cohen 2,406,000 sh (+88.28%)
Ken Fisher 134,180 sh (+71.99%)
Caxton Associates Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2017-06-30 Add 71.99%$6.96 - $9.07 $ 11.4740%134,180
Ken Fisher 2017-03-31 Add 18.76%$8.56 - $12.56 $ 11.478%78,014
Ken Fisher 2016-12-31 Reduce -51.66%$5.38 - $8.8 $ 11.4756%65,693
Joel Greenblatt 2016-12-31 Sold Out $5.38 - $8.8 $ 11.4756%0
Ken Fisher 2016-09-30 Add 0.15%$3.17 - $6.75 $ 11.47196%135,895
Joel Greenblatt 2016-09-30 New Buy$3.17 - $6.75 $ 11.47196%16,705
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RGEN, NYSE:CBM, NAS:CORT, NAS:MYOK, NAS:INSM, NAS:AKCA, NYSE:EBS, NAS:XLRN, NAS:INVA, NAS:BPMC, NAS:FOLD, NAS:HALO, NYSE:XON, NAS:SAGE, NAS:RARE, NYSE:BHVN, NAS:ICPT, NAS:LXRX, NAS:DVAX, NAS:IMMU » details
Traded in other countries:AR2.Germany,
Headquarter Location:USA
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.

Top Ranked Articles about Array BioPharma Inc

Array BioPharma To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference
Array BioPharma Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Array BioPharma Announces Pricing of Public Offering of Common Stock
Array BioPharma Announces Proposed Public Offering of Common Stock
Steven Cohen Dives Into Array BioPharma Guru keeps adding to positions in health care industry
On Sept. 11, Point72 manager Steven Cohen (Trades, Portfolio) invested in 6,766,507 shares of Array BioPharma Inc. (NASDAQ:ARRY), according to GuruFocus real-time picks. With this transaction, the guru increased his position 281.23%. Read more...
Array BioPharma Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug Applications For Patients With Advanced BRAF-mutant Melanoma
Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress
Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Colorectal Cancer Presented at European Society for Medical Oncology Congress
Array Biopharma To Present BEACON CRC Safety Lead-in And COLUMBUS Part 2 Results At European Society For Medical Oncology Congress (ESMO)
Array BioPharma To Present At The 2017 Wells Fargo Healthcare Conference

Ratios

vs
industry
vs
history
PB Ratio 166.18
ARRY's PB Ratio is ranked lower than
98% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ARRY: 166.18 )
Ranked among companies with meaningful PB Ratio only.
ARRY' s PB Ratio Range Over the Past 10 Years
Min: 3.52  Med: 19 Max: 168.64
Current: 166.18
3.52
168.64
PS Ratio 12.30
ARRY's PS Ratio is ranked higher than
59% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ARRY: 12.30 )
Ranked among companies with meaningful PS Ratio only.
ARRY' s PS Ratio Range Over the Past 10 Years
Min: 1.44  Med: 7.56 Max: 24.4
Current: 12.3
1.44
24.4
EV-to-EBIT -17.92
ARRY's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ARRY: -17.92 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -44  Med: -5.95 Max: 320.9
Current: -17.92
-44
320.9
EV-to-EBITDA -18.26
ARRY's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ARRY: -18.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -76.5  Med: -6.55 Max: 165.9
Current: -18.26
-76.5
165.9
EV-to-Revenue 12.38
ARRY's EV-to-Revenue is ranked higher than
60% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ARRY: 12.38 )
Ranked among companies with meaningful EV-to-Revenue only.
ARRY' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 7.45 Max: 27.9
Current: 12.38
2.1
27.9
Current Ratio 3.88
ARRY's Current Ratio is ranked lower than
55% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ARRY: 3.88 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.95 Max: 7.45
Current: 3.88
0.89
7.45
Quick Ratio 3.88
ARRY's Quick Ratio is ranked lower than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ARRY: 3.88 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.95 Max: 5.97
Current: 3.88
0.89
5.97
Days Sales Outstanding 75.68
ARRY's Days Sales Outstanding is ranked lower than
55% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. ARRY: 75.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.61  Med: 50.33 Max: 497.21
Current: 75.68
4.61
497.21
Days Payable 89.06
ARRY's Days Payable is ranked higher than
69% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. ARRY: 89.06 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 89.06
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.00
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ARRY: -9.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.65 Max: -4.2
Current: -9
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 573.50
ARRY's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ARRY: 573.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.24  Med: 7.03 Max: 582
Current: 573.5
2.24
582
Price-to-Tangible-Book 163.86
ARRY's Price-to-Tangible-Book is ranked lower than
98% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ARRY: 163.86 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 4.56 Max: 166.29
Current: 163.86
1.14
166.29
Price-to-Median-PS-Value 1.63
ARRY's Price-to-Median-PS-Value is ranked lower than
61% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ARRY: 1.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.87 Max: 2.6
Current: 1.63
0.23
2.6
Earnings Yield (Greenblatt) % -5.55
ARRY's Earnings Yield (Greenblatt) % is ranked higher than
51% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ARRY: -5.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.2  Med: -14.4 Max: 5.1
Current: -5.55
-95.2
5.1

More Statistics

Revenue (TTM) (Mil) $150.85
EPS (TTM) $ -0.73
Beta1.64
Short Percentage of Float16.24%
52-Week Range $3.49 - 13.40
Shares Outstanding (Mil)171.77

Analyst Estimate

Jun18
Revenue (Mil $)
EPS ($) -1.33
EPS without NRI ($) -1.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ARRY

Headlines

Articles On GuruFocus.com
Array BioPharma Announces Pricing of Public Offering of Common Stock Sep 14 2017 
Array BioPharma Announces Proposed Public Offering of Common Stock Sep 13 2017 
Steven Cohen Dives Into Array BioPharma Sep 13 2017 
Array BioPharma Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug Applicat Sep 12 2017 
Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical On Sep 09 2017 
Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Colorectal Cancer Presented at European Soc Sep 08 2017 
Array Biopharma To Present BEACON CRC Safety Lead-in And COLUMBUS Part 2 Results At European Society Aug 30 2017 
Array BioPharma To Present At The 2017 Wells Fargo Healthcare Conference Aug 28 2017 
Array BioPharma Appoints Curtis Oltmans As General Counsel Aug 14 2017 
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On A Aug 03 2017 

More From Other Websites
Cramer's lightning round: I like Altria Group, but it's n... Sep 20 2017
Array BioPharma To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference Sep 19 2017
Array BioPharma Announces Closing of Public Offering and Full Exercise of Option to Purchase... Sep 19 2017
Mirati Skyrockets On Positive Data - Biotech Movers Sep 15 2017
Today's Research Reports on Stocks to Watch: Halozyme Therapeutics and Array Biopharma Sep 15 2017
Array BioPharma Announces Pricing of Public Offering of Common Stock Sep 14 2017
Colorado biotech plans $200 million stock offering Sep 14 2017
Array BioPharma Slides on Secondary Offering Sep 14 2017
Array BioPharma shares slide on secondary offering announcement Sep 13 2017
Array BioPharma Announces Proposed Public Offering of Common Stock Sep 13 2017
Steven Cohen Dives Into Array BioPharma Sep 13 2017
Array's NDAs for Melanoma Combo Accepted for Review by FDA Sep 13 2017
Array BioPharma Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug... Sep 12 2017
See what the IHS Markit Score report has to say about Array Biopharma Inc. Sep 12 2017
ETFs with exposure to Array BioPharma, Inc. : September 12, 2017 Sep 11 2017
Array BioPharma And Others Shine At The ESMO 2017 Congress Sep 11 2017
Today's Research Reports on Stocks to Watch: Array BioPharma and Kura Oncology Sep 11 2017
Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical... Sep 09 2017
Array Resumes Trades After Unveiling Data In Colon Cancer Trial Sep 08 2017
Array BioPharma, Inc. :ARRY-US: Earnings Analysis: Q4, 2017 By the Numbers : September 8, 2017 Sep 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}